Roundview Capital LLC Purchases 933 Shares of Eli Lilly and Company $LLY

Key Points

• Roundview Capital LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 19.8% during the second quarter, acquiring an additional 933 shares to bring its total to 5,650 shares, worth approximately $4.4 million.
• Recent analyst reports show a mixed outlook on Eli Lilly, with Berenberg Bank lowering its price target from $970.00 to $830.00, while HSBC raised its target from $700.00 to $800.00.
• Insider trading activity includes Director J Erik Fyrwald purchasing 1,565 shares at an average cost of $642.33 per share, contributing to a recent trend of insider acquisitions totaling 4,514 shares valued at nearly $2.9 million.

Roundview Capital LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 19.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,650 shares of the company's stock after acquiring an additional 933 shares during the quarter. Roundview Capital LLC's holdings in Eli Lilly and Company were worth $4,404,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Eli Lilly and Company by 1.2% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,173 shares of the company's stock valued at $969,000 after acquiring an additional 14 shares during the last quarter. Wedge Capital Management L L P NC boosted its holdings in Eli Lilly and Company by 13.9% in the first quarter. Wedge Capital Management L L P NC now owns 738 shares of the company's stock valued at $610,000 after acquiring an additional 90 shares during the last quarter. Finally, Meridian Financial Partners LLC bought a new stake in Eli Lilly and Company in the first quarter valued at approximately $865,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Berenberg Bank reissued a "hold" rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. HSBC boosted their price target on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $938.94.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 over the last three months. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $845.40 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The stock's 50 day moving average is $735.35 and its 200-day moving average is $765.48. The firm has a market capitalization of $800.14 billion, a price-to-earnings ratio of 55.25, a PEG ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.